默沙东的Winrevair™ (Sotatercept-Csrk) 在针对心衰伴有保留射血分数 (Hfpef) 的成人的2期Cadence研究中达成主要指标

美股速递
Nov 18, 2025

默沙东的Winrevair™ (Sotatercept-Csrk) 在针对心衰伴有保留射血分数 (Hfpef) 的成人的2期Cadence研究中达成了主要指标,研究对象为合并后的肺动脉高压 (Cpcph) 患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10